News & Updates

Ustekinumab proven effective for ulcerative colitis

21 Feb 2020 by

Treatment with ustekinumab has been shown to be effective for ulcerative colitis (UC) in a real-world setting, according to a recent study presented at the 2020 Crohn’s and Colitis Congress (CCC 2020).

Ustekinumab proven effective for ulcerative colitis

21 Feb 2020

Cigarette smoking still more rampant than vaping among IBD patients

21 Feb 2020 by

E-cigarette use remains low among adult patients with inflammatory bowel disease (IBD), and among these users, conventional cigarette smoking still remains prevalent, according to a recent study presented at the Crohn’s and Colitis Congress (CCC) 2020.

Cigarette smoking still more rampant than vaping among IBD patients

21 Feb 2020

PPIs may induce flares, nonremission status in CD patients

20 Feb 2020 by

Use of proton pump inhibitors (PPIs) among patients with Crohn’s disease (CD) could increase their risk of interval flare and is associated with nonremission status, according to a study presented at the 2020 Crohn’s and Colitis Congress (CCC 2020).

PPIs may induce flares, nonremission status in CD patients

20 Feb 2020

Timing and causes of death from inflammatory bowel diseases

20 Feb 2020 by

Patients with Crohn’s disease (CD) seem to die at a younger age than people without inflammatory bowel disease (IBD), while those with ulcerative colitis (UC) die later, according to a recent study presented at the Crohn’s and Colitis Congress (CCC) 2020.

Timing and causes of death from inflammatory bowel diseases

20 Feb 2020

ENTERPRET: Vedolizumab found to have positive exposure–response pattern in UC

20 Feb 2020 by

Among patients with ulcerative colitis (UC), vedolizumab serum concentrations in the fifth week after treatment initiation appear to have been higher in those who do vs do not show response in the sixth week, according to interim data from ENTERPRET study presented at the 2020 Crohn’s and Colitis Congress (CCC).

ENTERPRET: Vedolizumab found to have positive exposure–response pattern in UC

20 Feb 2020

How does a low-fat, high-fibre diet influence ulcerative colitis?

19 Feb 2020 by

A diet low in fat and high in fibre seems well tolerated in patients with ulcerative colitis, not contributing to increased inflammation while significantly increasing populations of Faecalibacterium prausnitzii, according to a study presented at the 2020 Crohn's & Colitis Congress.

How does a low-fat, high-fibre diet influence ulcerative colitis?

19 Feb 2020

JAVELIN Gastric 100 fails to hit its main target in gastric cancer

18 Feb 2020 by

Maintenance therapy with the anti-PD-L1* checkpoint inhibitor avelumab failed to show superior overall survival (OS) compared with continuation chemotherapy (CT) following first-line** (1L) CT in patients with previously untreated, unresectable, and locally advanced/metastatic HER2-negative gastric or gastroesophageal cancer (GC/GEJC), according to the results of the phase III JAVELIN Gastric 100 trial presented at ASCO GI 2020.

JAVELIN Gastric 100 fails to hit its main target in gastric cancer

18 Feb 2020

Neoadjuvant SOX presents as option for advanced gastric cancer

17 Feb 2020 by

Neoadjuvant chemotherapy with S-1 and oxaliplatin (SOX) may be a suitable treatment measure for patients with advanced gastric or esophagogastric junction adenocarcinoma, according to the RESONANCE* trial presented at ASCO GI 2020.

Neoadjuvant SOX presents as option for advanced gastric cancer

17 Feb 2020

Tenofovir on par with entecavir for HCC prevention in CHB patients

17 Feb 2020

No significant difference is seen between entecavir and tenofovir disoproxil fumarate (TDF) in terms of their effectiveness for preventing hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB), according to a recent study.

Tenofovir on par with entecavir for HCC prevention in CHB patients

17 Feb 2020

$Faecal microbiota transplantation beneficial for survival in patients with refractory SFCDI$

Faecal microbiota transplantation beneficial for survival in patients with refractory SFCDI

17 Feb 2020

An inpatient faecal microbiota transplantation programme yields substantial reductions in Clostridioides difficile infection (CDI)-related mortality in patients with refractory severe or fulminant (SF) CDI, a study has found.

Faecal microbiota transplantation beneficial for survival in patients with refractory SFCDI

17 Feb 2020

News & Updates

Filter by Specialty:

Specialty:

Ustekinumab proven effective for ulcerative colitis

Ustekinumab proven effective for ulcerative colitis

Cigarette smoking still more rampant than vaping among IBD patients

Cigarette smoking still more rampant than vaping among IBD patients

PPIs may induce flares, nonremission status in CD patients

PPIs may induce flares, nonremission status in CD patients

Timing and causes of death from inflammatory bowel diseases

Timing and causes of death from inflammatory bowel diseases

ENTERPRET: Vedolizumab found to have positive exposure–response pattern in UC

ENTERPRET: Vedolizumab found to have positive exposure–response pattern in UC

How does a low-fat, high-fibre diet influence ulcerative colitis?

How does a low-fat, high-fibre diet influence ulcerative colitis?

JAVELIN Gastric 100 fails to hit its main target in gastric cancer

JAVELIN Gastric 100 fails to hit its main target in gastric cancer

Neoadjuvant SOX presents as option for advanced gastric cancer

Neoadjuvant SOX presents as option for advanced gastric cancer

Tenofovir on par with entecavir for HCC prevention in CHB patients

Tenofovir on par with entecavir for HCC prevention in CHB patients

Faecal microbiota transplantation beneficial for survival in patients with refractory SFCDI

Faecal microbiota transplantation beneficial for survival in patients with refractory SFCDI